SCHEMBL4243189

SCHEMBL4243189

CC(C)(C)OC(=O)NCc1ccccc1-c1ccc(N)cc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 8/20 0.56
KDM4A O75164 1/20 0.42
MALT1 Q9UDY8 1/20 0.38
IDO1 P14902 1/20 0.38
NAMPT P43490 2/20 0.38
GLS O94925 2/20 0.38
HDAC1 Q13547 1/20 0.37
PDK2 Q15119 1/20 0.37
BRD9 Q9H8M2 1/20 0.37
BAZ2B Q9UIF8 1/20 0.37
BAZ2A Q9UIF9 1/20 0.37
NQO2 P16083 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL498661 0.87 KCNA5 (0.67) KCNA5KDM4AMALT1
SCHEMBL4240163 0.85 KCNA5 (0.55) KCNA5KDM4APDK2
SCHEMBL2211731 0.84 KCNA5 (0.80) KCNA5MALT1NAMPT
SCHEMBL23762070 0.83 KCNA5 (0.46) KCNA5KDM4AMALT1IDO1NAMPT
SCHEMBL4242829 0.83 KCNA5 (0.53) KCNA5
SCHEMBL25470419 0.80 KCNA5 (0.51) KCNA5KDM4AMALT1NAMPTHDAC1
SCHEMBL1808874 0.79 KCNA5 (0.56) KCNA5KDM4AIDO1NAMPTHDAC1
SCHEMBL8254926 0.78 KCNA5 (0.61) KCNA5KDM4AMALT1IDO1NAMPT
SCHEMBL26659635 0.78 KCNA5 (0.55) KCNA5KDM4AIDO1NAMPTHDAC1
SCHEMBL12434473 0.77 KCNA5 (0.71) KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2004-05-27 US disclosed
US-6686395-B2 THERAPY OF A CARDIAC ARRYTHMIA WHICH CAN BE ELIMINATED BY ACTION POTENTIAL PROLONGATION; POTASSIUM CHANNEL MODULATOR AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-02-03 US disclosed
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed
US-6531495-B1 Potassium channel AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, KCNH1 KCNA5 104/4885KDM4A 2724/4885MALT1 1343/4885
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them MLLT3, RYR2, CACNA1E KCNA5 90/4885KDM4A 2758/4885MALT1 1282/4885
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, CACNA1E KCNA5 97/4885KDM4A 2791/4885MALT1 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.